Two years after its founding, Seal Rock Therapeutics is officially launching, with plans to bring its lead asset, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor it is developing for ...

Recent studies suggest that adult humans have active brown or beige adipocytes, the activation of which might be a therapeutic strategy for the treatment of diverse metabolic diseases. Here we show ...

Researchers from the University of Zurich presented data from a study that aimed to investigate the impact of liver-specific apoptosis signal regulating kinase 1 (ASK1) overexpression on the ...

Genfit has added a third liver failure candidate to its portfolio courtesy of a licensing deal with Seal Rock Therapeutics potentially worth up to 100 million euros ($107 million) in biobucks. The ...